As of 2024-12-12, the Relative Valuation of Reneo Pharmaceuticals Inc (RPHM) is (8.99) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.82 USD, the upside of Reneo Pharmaceuticals Inc based on Relative Valuation is -594.0%.
The range of the Relative Valuation is (9.14) - (9.48) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 16.7x - 24.9x | 18.3x |
| Forward P/E multiples | 19.4x - 20.1x | 19.9x |
| Fair Price | (9.14) - (9.48) | (8.99) |
| Upside | -602.2% - -620.9% | -594.0% |
| Date | P/E |
| 2024-11-15 | -35.27 |
| 2024-11-14 | -35.91 |
| 2024-11-13 | -35.86 |
| 2024-11-12 | -36.73 |
| 2024-11-11 | -37.29 |
| 2024-11-08 | -37.35 |
| 2024-11-07 | -36.52 |
| 2024-11-06 | -36.10 |
| 2024-11-05 | -37.41 |
| 2024-11-04 | -34.67 |
| 2024-11-01 | -34.61 |
| 2024-10-31 | -37.18 |
| 2024-10-30 | -37.16 |
| 2024-10-29 | -37.97 |
| 2024-10-28 | -36.88 |
| 2024-10-25 | -36.18 |
| 2024-10-24 | -36.50 |
| 2024-10-23 | -39.09 |
| 2024-10-22 | -40.01 |
| 2024-10-21 | -39.41 |
| 2024-10-18 | -39.33 |
| 2024-10-17 | -38.14 |
| 2024-10-16 | -39.50 |
| 2024-10-15 | -39.84 |
| 2024-10-14 | -39.71 |
| 2024-10-11 | -39.13 |
| 2024-10-10 | -40.37 |
| 2024-10-09 | -39.30 |
| 2024-10-08 | -40.81 |
| 2024-10-07 | -39.62 |
| 2024-10-04 | -38.67 |
| 2024-10-03 | -36.76 |
| 2024-10-02 | -35.06 |
| 2024-10-01 | -3.63 |
| 2024-09-30 | -3.61 |
| 2024-09-27 | -3.53 |
| 2024-09-26 | -3.44 |
| 2024-09-25 | -3.25 |
| 2024-09-24 | -3.00 |
| 2024-09-23 | -2.93 |
| 2024-09-20 | -3.19 |
| 2024-09-19 | -3.21 |
| 2024-09-18 | -3.19 |
| 2024-09-17 | -2.95 |
| 2024-09-16 | -2.91 |
| 2024-09-13 | -2.78 |
| 2024-09-12 | -3.00 |
| 2024-09-11 | -3.00 |
| 2024-09-10 | -3.02 |
| 2024-09-09 | -3.04 |